Endomag selected as finalist for top engineering award
Cancer healthcare company Endomag has been revealed as a finalist for the UK’s most prestigious engineering award.
Endomag opens two new offices due to rapid expansion
The cancer healthcare company Endomag has relocated its Cambridge headquarters to larger offices in the prestigious Jeffreys Building, St John’s Innovation Park, due to its rapid growth this year.
Endomag’s Sentimag® trial begins in the US
Endomag, the cancer healthcare company, has announced the completion of the first procedures in the USA using its Sentimag® and Sienna+® system for staging breast cancer, marking the start of its pivotal clinical trial.
Endomag presents at influential OneMedForum in San Francisco
Endomag, the cancer healthcare company, will be presenting plans for its global expansion at the OneMedForum this month.
Endomagnetics becomes Endomag as business expands into new markets
Endomagnetics is today revealing a new brand identity that accurately reflects its position as a global leader in the development of devices for cancer care based on the application of advanced magnetic technologies.
Endomagnetics receives IDE approval to initiate US trials
Cancer healthcare company Endomagnetics announced today that it has received Investigational Device Exemption (IDE) approval from the United States Food and Drug Administration (FDA) to initiate a pivotal clinical trial to evaluate the safety and effectiveness of the SentiMag® and Sienna+® magnetic sentinel lymph node biopsy system in the management of breast cancer.
Endomagnetics raises funding for US clinical trial, sales support and new product development
Endomagnetics, the Cambridge-based cancer healthcare company, has raised a further £2m ($3.12m US) to support its pivotal US clinical trial and the launch of a new cancer marker product in 2015.
SentiMag® now available in Australia and New Zealand
Endomagnetics is pleased to announce it has reached an agreement with Aurora BioScience as its exclusive distributor for Australia and New Zealand. This appointment significantly extends the availability of the company’s SentiMag® and Sienna+® tracer system. Breast cancer patients in the region will now have access to new technology that optimally locates lymph nodes as part of the cancer…
Endomagnetics completes acquisition of the ACT portfolio
Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, announced today the acquisition of the ACT portfolio and related assets from Actium Biosystems, LLC. This move extends Endomagnetics’ oncology platform from diagnostics into therapeutics while maintaining synergies with its magnetic nanoparticle technology.
Endomagnetics introduces higher performance probe and appoints CTO
Endomagnetics, the company developing a portfolio of products to improve the standard of cancer care, has developed a new, higher performance probe for its popular SentiMag® instrument.
Endomagnetics wins Business Weekly award for 'Best New Product'
Endomagnetics, the company enjoying international commercial success with its medical device technology, has been given the award for Best New Product or Business Model in this year’s Business Weekly awards. The award was made at a gala dinner at Queens’ College, Cambridge last week.
Endomagnetics appoints strategic distributor
Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has announced it has signed a distribution agreement with Sysmex Europe GmbH, a subsidiary of global healthcare company Sysmex Corporation.
Endomagnetics announces quality certification and COO appointment
Endomagnetics, the company developing a portfolio of products to improve the standard of breast cancer management, has achieved certification to an international quality standard.
Endomagnetics awarded funding to explore melanoma detection
Endomagnetics, the company known for developing magnetic technology for use in breast cancer staging, has been awarded government funding to extend its application to another form of cancer. The project will explore the clinical feasibility of applying magnetic sentinel lymph node (SLN) detection to melanoma, a significant cancer with more than 116,000 cases per year in the EU and US alone (WHO),…
Endomagnetics selected for Britain showcase
Cambridge-based Endomagnetics has been selected to represent the excellence of British business in a Life Sciences Sector Summit on 2nd August. Clinicians and hospital administrators will be eager to see how magnetic sensing technology can make a major difference in extending the availability of key cancer staging techniques.
Endomagnetics expands its horizons
Cambridge company Endomagnetics is receiving enquiries from across the world after it featured on the BBC World 'Horizons' programme recently.
Endomagnetics founder wins 2012 ACES Life Sciences Award
Endomagnetics and one of its founders has picked up a major accolade by being recognised in the Science Business Academic Enterprise Awards (ACES).